Preterm newborns exposed to early-onset preeclampsia have altered postnatal Tumor Necrosis Factor-related apoptosis-inducing ligand trends versus controls.
Journal
Pediatric research
ISSN: 1530-0447
Titre abrégé: Pediatr Res
Pays: United States
ID NLM: 0100714
Informations de publication
Date de publication:
Jun 2023
Jun 2023
Historique:
received:
09
11
2021
accepted:
27
08
2022
revised:
27
07
2022
medline:
3
7
2023
pubmed:
5
10
2022
entrez:
4
10
2022
Statut:
ppublish
Résumé
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a protein with anti-atherogenic and vasoprotective effects that has never been studied in newborns exposed to preeclampsia. Our aim was to examine TRAIL serum concentrations in such neonates after birth and during the transitional period. Serum TRAIL levels were measured on the first and fifth day of life (DOL1 and DOL5, respectively) in 38 newborns exposed to early-onset preeclampsia and 38 controls born of normotensive mothers. TRAIL values on DOL1 and DOL5 did not differ between cases and controls. However, from DOL1 to DOL5 TRAIL levels increased in controls (from 20.54 ± 7.35 to 23.93 ± 11.02 pg/ml, p = 0.044) but decreased in those exposed to preeclampsia (from 25.58 ± 15.74 to 20.53 ± 10.72 pg/ml, p = 0.035). Overall, the relative change of TRAIL values from DOL1 to DOL5 was positively related to birth weight (beta coefficient 0.234, p = 0.042) and inversely related to preeclampsia (beta coefficient -0.241, p = 0.036). Newborns exposed to early-onset preeclampsia present a decrease in serum TRAIL levels during the transitional period. This pattern is exactly the opposite from what is observed in neonates born to normotensive mothers, and most likely points towards a defective mechanism of extrauterine adaptation related to preeclampsia exposure in utero. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) levels during the transitional period do not differ between infants exposed to early-onset preeclampsia and controls The pattern of change of TRAIL levels after birth is different; TRAIL decreases in newborns exposed to preeclampsia but increases in controls The decrease of TRAIL levels during the transitional period points towards a defective mechanism of extrauterine adaptation and an altered cardiometabolic profile in newborns exposed to early-onset preeclampsia.
Sections du résumé
BACKGROUND
BACKGROUND
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a protein with anti-atherogenic and vasoprotective effects that has never been studied in newborns exposed to preeclampsia. Our aim was to examine TRAIL serum concentrations in such neonates after birth and during the transitional period.
METHODS
METHODS
Serum TRAIL levels were measured on the first and fifth day of life (DOL1 and DOL5, respectively) in 38 newborns exposed to early-onset preeclampsia and 38 controls born of normotensive mothers.
RESULTS
RESULTS
TRAIL values on DOL1 and DOL5 did not differ between cases and controls. However, from DOL1 to DOL5 TRAIL levels increased in controls (from 20.54 ± 7.35 to 23.93 ± 11.02 pg/ml, p = 0.044) but decreased in those exposed to preeclampsia (from 25.58 ± 15.74 to 20.53 ± 10.72 pg/ml, p = 0.035). Overall, the relative change of TRAIL values from DOL1 to DOL5 was positively related to birth weight (beta coefficient 0.234, p = 0.042) and inversely related to preeclampsia (beta coefficient -0.241, p = 0.036).
CONCLUSION
CONCLUSIONS
Newborns exposed to early-onset preeclampsia present a decrease in serum TRAIL levels during the transitional period. This pattern is exactly the opposite from what is observed in neonates born to normotensive mothers, and most likely points towards a defective mechanism of extrauterine adaptation related to preeclampsia exposure in utero.
IMPACT
CONCLUSIONS
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) levels during the transitional period do not differ between infants exposed to early-onset preeclampsia and controls The pattern of change of TRAIL levels after birth is different; TRAIL decreases in newborns exposed to preeclampsia but increases in controls The decrease of TRAIL levels during the transitional period points towards a defective mechanism of extrauterine adaptation and an altered cardiometabolic profile in newborns exposed to early-onset preeclampsia.
Identifiants
pubmed: 36195627
doi: 10.1038/s41390-022-02301-7
pii: 10.1038/s41390-022-02301-7
doi:
Substances chimiques
Ligands
0
TNF-Related Apoptosis-Inducing Ligand
0
Tumor Necrosis Factor-alpha
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1955-1958Informations de copyright
© 2022. The Author(s), under exclusive licence to the International Pediatric Research Foundation, Inc.
Références
Mol, B. W. J. et al. Pre-eclampsia. Lancet 387, 999–1011 (2016).
doi: 10.1016/S0140-6736(15)00070-7
pubmed: 26342729
Raymond, D. & Peterson, E. A critical review of early-onset and late-onset preeclampsia. Obstet. Gynecol. Surv. 66, 497–506 (2011).
doi: 10.1097/OGX.0b013e3182331028
pubmed: 22018452
Bokslag, A., van Weissenbruch, M., Mol, B. W. & de Groot, C. J. Preeclampsia; short and long-term consequences for mother and neonate. Early Hum. Dev. 102, 47–50 (2016).
doi: 10.1016/j.earlhumdev.2016.09.007
pubmed: 27659865
Story, L. & Chappell, L. C. Preterm pre-eclampsia: What every neonatologist should know. Early Hum. Dev. 114, 26–30 (2017).
doi: 10.1016/j.earlhumdev.2017.09.010
pubmed: 28917582
Backes, C. H. et al. Maternal preeclampsia and neonatal outcomes. J. Pregnancy. 2011, 214365. (2011).
Amaral, L. M., Cunningham, M. W. Jr, Cornelius, D. C. & LaMarca, B. Preeclampsia: long-term consequences for vascular health. Vasc. Health Risk. Manag. 11, 403–415 (2015).
pubmed: 26203257
pmcid: 4508084
Karatza, A. A. & Dimitriou, G. Preeclampsia emerging as a novel risk factor for cardiovascular disease in the offspring. Curr. Pediatr. Rev. 16, 194–199 (2020).
pubmed: 31884930
pmcid: 8193805
Davis, E. F. et al. Pre-eclampsia and offspring cardiovascular health: mechanistic insights from experimental studies. Clin. Sci. (Lond.) 123, 53–72 (2012).
doi: 10.1042/CS20110627
pubmed: 22455350
Hofbauer, L. C. & Schoppet, M. Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. JAMA 292, 490–495 (2004).
doi: 10.1001/jama.292.4.490
pubmed: 15280347
Venuraju, S. M., Yerramasu, A., Corder, R. & Lahiri, A. Osteoprotegerin as a predictor of coronary artery disease and cardiovascular mortality and morbidity. JACC 55, 2049–2061 (2010).
doi: 10.1016/j.jacc.2010.03.013
pubmed: 20447527
Montagnana, M., Lippi, G., Danese, E. & Guidi, G. C. The role of osteoprotegerin in cardiovascular disease. Ann. Med. 45, 254–264 (2013).
doi: 10.3109/07853890.2012.727019
pubmed: 23110639
Perez de Ciriza, C., Lawrie, A. & Varo, N. Osteoprotegerin in cardiometabolic disorders. Int. J. Endocrinol., 2015, Article ID 564934 (2015).
Bernardi, S., Bossi, F., Toffoli, B. & Fabris, B. Roles and Clinical Applications of OPG and TRAIL as Biomarkers in Cardiovascular Disease. Biomed. Res. Int. 2016, 1752854 (2016).
doi: 10.1155/2016/1752854
pubmed: 27200369
pmcid: 4856888
Secchiero, P. et al. Potential prognostic significance of decreased serum levels of TRAIL after acute myocardial infarction. PLoS. One. 4, e4442 (2009).
doi: 10.1371/journal.pone.0004442
pubmed: 19221598
pmcid: 2637972
Almasan, A. & Ashkenazi, A. Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy. Cytokine. Growth Factor. Rev. 14, 337–348 (2003).
doi: 10.1016/S1359-6101(03)00029-7
Blanco, O., Leno-Durán, E., Morales, J. C., Olivares, E. G. & Ruiz-Ruiz, C. Human decidual stromal cells protect lymphocytes from apoptosis. Placenta 30, 677–685 (2009).
doi: 10.1016/j.placenta.2009.05.011
pubmed: 19560201
Morano, D. et al. Lower maternal serum tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) levels in early preeclampsia. A retrospective study. Pregnancy Hypertens. 12, 1–5 (2018).
doi: 10.1016/j.preghy.2018.02.002
pubmed: 29674187
Zauli, G. et al. The circulating levels of TRAIL are extremely low after delivery but rapidly recover in both mothers and newborns. Cytokine 64, 51–53 (2013).
doi: 10.1016/j.cyto.2013.05.005
pubmed: 23722000
Report of the American College of Obstetricians and Gynecologists’ Task Force on Hypertension in Pregnancy. Hypertension in pregnancy: executive summary. Obstet. Gynecol. 122, 1122–1131 (2013).
doi: 10.1097/01.AOG.0000437382.03963.88
Chou, J. H., Roumiantsev, S. & Singh, R. PediTools electronic growth chart calculators: applications in clinical care, research, and quality improvement. J. Med. Internet Res. 22, e16204 (2020).
doi: 10.2196/16204
pubmed: 32012066
pmcid: 7058170
Marsters, S. A., Pitti, R. A., Sheridan, J. P. & Ashkenazi, A. Control of apoptosis signaling by Apo2 ligand. Recent. Prog. Horm. Res. 54, 225–234 (1999).
pubmed: 10548878
Lorz, C., Benito, A., Ucero, A. C., Santamaría, B. & Ortiz, A. Trail and kidney disease Front. Biosci. (Landmark Ed.) 14, 3740–3749 (2009).
doi: 10.2741/3485
Phillips, T. A. et al. TRAIL (Apo-2L) and TRAIL receptors in human placentas: implications for immune privilege. J. Immunol. 162, 6053–6059 (1999).
doi: 10.4049/jimmunol.162.10.6053
pubmed: 10229846
Chen, L. et al. Localization and variation of TRAIL and its receptors in human placenta during gestation. Life. Sci. 74, 1479–1486 (2004).
doi: 10.1016/j.lfs.2003.07.044
pubmed: 14729397
Spradley, F. T. Metabolic abnormalities and obesity’s impact on the risk for developing preeclampsia. Am. J. Physiol. Regul. Integr. Comp. Physiol. 312, R5–R12 (2017).
doi: 10.1152/ajpregu.00440.2016
pubmed: 27903516
Harith, H. H., Morris, M. J. & Kavurma, M. M. On the TRAIL of obesity and diabetes. Trends Endocrinol. Metab. 24, 578–587 (2013).
doi: 10.1016/j.tem.2013.07.001
pubmed: 23948591
Oikonomou, N. et al. Osteoprotegerin and RANKL serum concentrations in neonates of mothers with early-onset pre-eclampsia: comparison with neonates of normotensive mothers. Early Hum. Dev. 135, 1–5 (2019).
doi: 10.1016/j.earlhumdev.2019.06.001
pubmed: 31176082
Oikonomou, N. et al. Aortic intima-media thickness in neonates exposed to early-onset preeclampsia. Early Hum. Dev. 151, 105166 (2020).
doi: 10.1016/j.earlhumdev.2020.105166
pubmed: 32889166
Chourdakis, E. et al. Effect of early-onset preeclampsia on offspring’s blood pressure during the first month of life. J. Pediatr. 220, 21–26.e1 (2020).
doi: 10.1016/j.jpeds.2020.01.033
pubmed: 32093926